Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Phase 4CompletedNCT00190879

Eli Lilly and Company440 enrolled

Overview

To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

440

Conditions

Attention Deficit Hyperactivity Disorder Comorbid Social Anxiety Disorder

Interventions

Atomoxetine hydrochlorideDRUG

placeboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * You must be 18 to 65 years old. * You must have been diagnosed with attention deficit hyperactivity disorder and social anxiety disorder. * You must be able to visit the doctor's office at least 8 times over a 16 week period. * You must agree to participate with all tests and examinations that are required for this study. Exclusion Criteria: * You are a woman and pregnant or breastfeeding. * You presently have an acute or unstable medical illness. * You have a history of allergic reaction to atomoxetine hydrochloride. * You are taking medications that are not permitted in this study. Your physician will discuss these with you. * You have taken part in another clinical research trial within the last 30 days or have received treatment with a drug in the last 30 days that has not received regulatory approval.

Locations (21)

Outcomes

Primary Outcomes

Reduction in signs and symptoms of ADHD as measured by the mean changes from baseline to endpoint in Conner's adult ADHD rating scale

Secondary Outcomes

Reduction in signs and symptoms of social anxiety as measured by the mean changes from baseline to endpoint in Liebowitz social anxiety scale

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Wildomar, California, United States

Bradenton, Florida, United States

Gainesville, Florida, United States

Lexington, Kentucky, United States

Belmont, Massachusetts, United States

Okemos, Michigan, United States

Rochester Hills, Michigan, United States

Saint Charles, Missouri, United States

Nashua, New Hampshire, United States

Cherry Hill, New Jersey, United States

...and 11 more locations